Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lopinavir/ritonavir sprinkle formulation - Cipla

Drug Profile

Lopinavir/ritonavir sprinkle formulation - Cipla

Alternative Names: Lopimune Sprinkles; Lopinavir/ritonavir mini-melt tablets formulation; Lopinavir/ritonavir oral pellets; Ritonavir/lopinavir

Latest Information Update: 26 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cipla
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation
  • Class Amides; Antiretrovirals; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV-1 infections
  • No development reported HIV infections

Most Recent Events

  • 26 Oct 2018 Lopinavir/ritonavir sprinkle formulation is still in phase III trials for HIV-1 infections (In children) in Kenya, Uganda and Tanzania (PO) (NCT02346487)
  • 26 Oct 2018 No development reported - Preregistration for HIV-1 infections (In adolescents, In children, In infants, In neonates) in USA (PO)
  • 01 Dec 2015 Phase-III clinical trials in HIV-1 infections (In children) in Kenya (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top